Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Wellcome's Flolan

Executive Summary

Wellcome's Flolan: Antihypertensive drug epoprostenol is "approvable" at FDA for treatment of severe primary pulmonary hypertension but not for congestive heart failure patients with left ventricular systolic dysfunction as reported in the May 15 issue of "The Pink Sheet" (In Brief). Trials of Flolan for patients with severe end-stage congestive heart failure were halted when interim analyses showed Flolan patients had higher mortality rates than those receiving standard therapies ("The Pink Sheet" June 28, 1993, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel